Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

InMed Pharmaceuticals (INM) Other Gross PP&E Adjustments (2019 - 2025)

InMed Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 5 years, most recently at $2.3 million for Q2 2025.

  • For Q2 2025, Other Gross PP&E Adjustments fell 10.55% year-over-year to $2.3 million; the TTM value through Jun 2025 reached $2.3 million, down 10.55%, while the annual FY2025 figure was $2.3 million, 10.55% down from the prior year.
  • Other Gross PP&E Adjustments for Q2 2025 was $2.3 million at InMed Pharmaceuticals, roughly flat from $2.3 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $2.6 million in Q1 2024 and troughed at $40409.0 in Q4 2023.
  • A 5-year average of $1.6 million and a median of $1.6 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: plummeted 97.16% in 2023 and later skyrocketed 5767.98% in 2024.
  • Year by year, Other Gross PP&E Adjustments stood at $1.4 million in 2021, then rose by 0.25% to $1.4 million in 2022, then plummeted by 97.16% to $40409.0 in 2023, then skyrocketed by 5767.98% to $2.4 million in 2024, then dropped by 1.71% to $2.3 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for INM at $2.3 million in Q2 2025, $2.3 million in Q1 2025, and $2.4 million in Q4 2024.